CDNA — CareDx, Inc

CareDx, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $108.4 million, up 25% year-over-year.
• Testing Services Revenue: $78.4 million, a 23% increase from the prior year; testing volume grew 17% to approximately 53,000 tests.
• Non-GAAP Gross Margin: 68.5% for Q4; full-year gross margin at 69.3%.
• Adjusted EBITDA: $6.5 million for Q4, down 34% year-over-year; full-year adjusted EBITDA of $31.7 million, a 14% increase.
• Cash Position: Ended Q4 with $201.4 million in cash and no debt; repurchased $12 million in stock during the quarter and $88 million for the year.

2. Strategic Updates and Business Highlights:

• Product Launches: Introduced AlloSure Heart for Pediatrics, Alisure Plus for kidney transplant risk assessment, and HistoMAP Kidney for rejection subtype identification.
• Revenue Cycle Management (RCM): Improved collections and reduced claim rejection rates significantly, enhancing cash flow.
• Patient and Digital Solutions: Revenue surged 47% year-over-year to $16.8 million, reflecting strong demand for integrated solutions.
• Lab Products: Revenue increased 17% year-over-year to $13.3 million, driven by ongoing adoption of HLA typing solutions.
• Epic Aura Integration: Seven transplant centers are live with Epic Aura, with expectations of improved operational efficiency and customer experience.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected between $420 million and $444 million, representing approximately 14% year-over-year growth.
• Testing Services Revenue Guidance: Anticipated between $306 million and $326 million, with testing volume projected at 220,000 to 228,000 tests.
• Adjusted EBITDA Guidance: Expected between $30 million and $45 million, reflecting a potential 20% increase at the midpoint.
• Impact of LCD: A projected $7.5 million revenue reduction due to the draft local coverage determination affecting reimbursement policies.

4. Bad News, Challenges, or Points of Concern:

• Reimbursement Risks: The draft LCD may negatively impact revenue, particularly for AlloMap Heart, which could affect testing volumes and margins.
• Growth Projections: The guidance for testing volume growth at 12% is considered conservative compared to the 17% exit rate, raising concerns about future growth momentum.
• Leadership Transition: CFO Nathan Smith announced his departure, which may introduce uncertainty in financial strategy execution.

5. Notable Q&A Insights:

• Volume Guidance: Management does not expect an increase in transplant procedural volume in 2026 and remains cautious about the impact of Epic Aura integrations on future growth.
• Patient and Digital Solutions: The segment is expected to grow 8% to 12% in 2026, with margins in the 60-70% range for software products.
• Strategic Investments: $10 million is allocated for upgrading enterprise systems, which is expected to enhance operational efficiency and long-term growth.
• Market Dynamics: Management believes the demand for kidney transplants will remain strong despite the potential impact of GLP-1 medications on kidney disease prevalence.

Overall, CareDx, Inc. reported strong financial performance in Q4 2025, with strategic initiatives aimed at sustaining growth. However, challenges related to reimbursement policies and leadership changes may pose risks to future performance.